Healthcare & Life Sciences
Intellia Therapeutics
Intellia Therapeutics is a CRISPR gene-editing company that reported Phase 3 success in April 2026 for lonvo-z, an in vivo CRISPR therapy that inactivates a liver gene to reduce hereditary angioedema (HAE) swelling attacks -- an 87% reduction in attack rate versus placebo across an 80-patient study, with 62% of treated patients attack-free and therapy-free versus 11% on placebo. Intellia has begun a rolling FDA submission seeking approval of what could become the first in vivo gene-editing therapy to reach market for any disease, targeting a 2027 launch if approved, with a favorable safety profile limited mainly to infusion-related reactions, headaches and fatigue.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 49% avg. source confidence
- CNBC / STAT News — Intellia's CRISPR gene-editing treatment succeeds in Phase 3 trial for hereditary angioedema54% source confidence
- Wall Street Reporter — Intellia stock surges 38% as rolling BLA nears completion under RMAT designation44% source confidence
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Jul 28, 2026
Dependency Map
What Intellia Therapeutics depends on below, and who depends on Intellia Therapeutics above — click any node to make it the new center, 3 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Intellia Therapeutics's Timeline
A sourced, dated history of Intellia Therapeutics's key moments — founding to present.
Apr 2026 · Begins rolling FDA submission for first in vivo gene-editing therapy
Based on its Phase 3 data, Intellia began a rolling FDA submission for lonvo-z, positioning it as a candidate to become the first in vivo CRISPR gene-editing therapy approved for any disease, with a planned 2027 launch if approved.
Apr 2026 · Lonvo-z succeeds in Phase 3 trial for hereditary angioedema
Intellia reported that lonvo-z, its in vivo CRISPR-based therapy inactivating a liver gene to reduce the protein driving hereditary angioedema swelling attacks, succeeded in an 80-patient Phase 3 trial, cutting attack rates by 87% versus placebo, with 62% of treated patients attack-free and therapy-free versus 11% in the control arm.
Jul 2026 · Stock surges 38% as RMAT-designated rolling BLA nears completion
Intellia's stock surged 38% over the prior month as investors anticipated a U.S. launch in the first half of 2027; the company expects to complete its rolling Biologics License Application for lonvo-z in the second half of 2026 under the FDA's regenerative medicine advanced therapy (RMAT) designation, which allows portions of the BLA to be submitted on an ongoing basis and provides the FDA an opportunity to accelerate review.